NeuroPace
Developing and marketing implantable devices for the treatment of neurological disorders.
loading funding rounds…
MedVenture Associates(exited)
Kleiner Perkins(exited)
InterWest Partners(exited)
Johnson & Johnson(exited)
NEA(exited)
OrbiMed(exited)
KCK(exited)
Accelmed(exited)
Revelation Partners(exited)
Soleus Capital(exited)
Domain Associates(exited)
Medventure(exited)
Technology Partners(exited)
Emory University(exited)
CRG LP(exited)
Armentum Partners(exited)
UCLA Ventures(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 10 % | 1 % | 44 % | 22 % | 19 % | 11 % | 27 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (63 %) | (87 %) | (35 %) | (21 %) | (14 %) | (6 %) | 2 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (80 %) | (103 %) | (50 %) | (34 %) | (28 %) | (19 %) | (7 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 40 % | 48 % | 32 % | 30 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.